Comparison of the anti-inflammatory activity and effect on intraocular pressure of fluoromethalone, clobetasone butyrate and betamethasone phosphate eye drops.
The effect of fluoromethalone 0.1% suspension (FML), clobetasone butyrate 0.1% (Eumovate) and betamethasone phosphate 0.1% (Betnesol) in post-operative inflammation was studied in 60 eyes (50 patients) in a randomized trial. No significant differences were noted, although two patients required higher penetration steroids than FML or Eumovate. Betnesol seemed to have a greater tendency to cause raised intraocular pressure than FML. In this series, however, the authors are unable to comment on differences between Eumovate and Betnesol.
D000368:Aged; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D002990:Clobetasol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004311:Double-Blind Method; D005469:Fluorometholone / Q000627:therapeutic use*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control*; D014605:Uveitis / Q000517:prevention & control*
C028994:betamethasone sodium phosphate; C010893:clobetasone butyrate; D001623:Betamethasone; D002990:Clobetasol; D005469:Fluorometholone